Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||HuCART-meso cells + VCN-01|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|HuCART-meso cells||anti-MSLN CAR-T Cells||HuCART-meso cells are T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) that targets mesothelin and contains the zeta chain of CD3 (CD3zeta) and other costimulatory domains, which potentially leads to increased antitumor immune response (PMID: 26973126, PMID: 31420241).|
|VCN-01||VCN-01 is a replication-competent oncolytic adenovirus that may lead to decreased tumor cell viability and reduced tumor growth (PMID: 26603261), particularly in tumors with a dysfunctional RB1 pathway (PMID: 30674657).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05057715||Phase I||HuCART-meso cells + VCN-01||huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer||Recruiting||USA||0|